Global Induced Pluripotent Stem Cells Production Market 2024-2028

Description

List of Tables

The induced pluripotent stem cells production market is forecasted to grow by USD 1841.79 mn during 2023-2028, accelerating at a CAGR of 11.66% during the forecast period. The report on the induced pluripotent stem cells production market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of several chronic disorders, increasing adoption of ipscs in drug discovery and toxicity screening applications, and growing demand for ipscs for personalized medicines.

Technavio's induced pluripotent stem cells production market is segmented as below:

Market Scope
Base Year	2024
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	10.09%
CAGR	11.66%
Incremental Value	$1841.79mn

By End-user

Hospitals
Research institutes
Biotechnology companies
Others

By Product

Consumable and kits
Instrument
Services and others

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the advancements in cell reprogramming techniques as one of the prime reasons driving the induced pluripotent stem cells production market growth during the next few years. Also, emergence of ipsc banks and repositories and growing applications of ipscs in regenerative medicine will lead to sizable demand in the market.

The report on the induced pluripotent stem cells production market covers the following areas:

Induced pluripotent stem cells production market sizing
Induced pluripotent stem cells production market forecast
Induced pluripotent stem cells production market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading induced pluripotent stem cells production market vendors that include Allele Biotechnology and Pharmaceuticals Inc., ALSTEM, Applied Biological Materials Inc., Applied StemCell, ATCC, Axol Biosciences Ltd., Becton Dickinson and Co., Bio Techne Corp., Board of Regents of the University of Wisconsin System, Creative Biolabs, Cyagen Biosciences, Cynata Therapeutics Ltd., Evotec SE, Fate Therapeutics Inc., FUJIFILM Corp., Hitachi Ltd., LIFE and BRAIN GmbH, Lonza Group Ltd., Ncardia Services B.V., REPROCELL Inc., Sartorius AG, STEMCELL Technologies Inc., Takara Bio Inc., and Thermo Fisher Scientific Inc.. Also, the induced pluripotent stem cells production market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR71329

1 Executive Summary

1.1 Market overview

2 Market Landscape

2.1 Market ecosystem

3 Market Sizing

3.1 Market definition
3.2 Market segment analysis
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028

4 Historic Market Size

4.1 Global induced pluripotent stem cells production market 2018 - 2022
4.2 End-user Segment Analysis 2018 - 2022
4.3 Product Segment Analysis 2018 - 2022
4.4 Geography Segment Analysis 2018 - 2022
4.5 Country Segment Analysis 2018 - 2022

5 Five Forces Analysis

5.1 Five forces summary
5.2 Bargaining power of buyers
5.3 Bargaining power of suppliers
5.4 Threat of new entrants
5.5 Threat of substitutes
5.6 Threat of rivalry
5.7 Market condition

6 Market Segmentation by End-user

6.1 Market segments
6.2 Comparison by End-user
6.3 Hospitals - Market size and forecast 2023-2028
6.4 Research institutes - Market size and forecast 2023-2028
6.5 Biotechnology companies - Market size and forecast 2023-2028
6.6 Others - Market size and forecast 2023-2028
6.7 Market opportunity by End-user

7 Market Segmentation by Product

7.1 Market segments
7.2 Comparison by Product
7.3 Consumable and kits - Market size and forecast 2023-2028
7.4 Instrument - Market size and forecast 2023-2028
7.5 Services and others - Market size and forecast 2023-2028
7.6 Market opportunity by Product

8 Customer Landscape

8.1 Customer landscape overview

9 Geographic Landscape

9.1 Geographic segmentation
9.2 Geographic comparison
9.3 North America - Market size and forecast 2023-2028
9.4 Europe - Market size and forecast 2023-2028
9.5 Asia - Market size and forecast 2023-2028
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
9.7 US - Market size and forecast 2023-2028
9.8 China - Market size and forecast 2023-2028
9.9 UK - Market size and forecast 2023-2028
9.10 Germany - Market size and forecast 2023-2028
9.11 Canada - Market size and forecast 2023-2028
9.12 Market opportunity By Geographical Landscape

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
11.3 Landscape disruption
11.4 Industry risks

12 Vendor Analysis

12.1 Vendors covered
12.2 Market positioning of vendors
12.3 Allele Biotechnology and Pharmaceuticals Inc.
12.4 Applied Biological Materials Inc.
12.5 Applied StemCell
12.6 ATCC
12.7 Axol Biosciences Ltd.
12.8 Cynata Therapeutics Ltd.
12.9 Evotec SE
12.10 Fate Therapeutics Inc.
12.11 FUJIFILM Corp.
12.12 Hitachi Ltd.
12.13 LIFE and BRAIN GmbH
12.14 Lonza Group Ltd.
12.15 Ncardia Services B.V.
12.16 REPROCELL Inc.
12.17 Takara Bio Inc.

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
13.3 Currency conversion rates for US$
13.4 Research methodology
13.5 List of abbreviations